Novo Nordisk A/S (NVO) Stock Forecast & Price Target

NVO Forecast - Frequently Asked Questions

What is Novo Nordisk A/S's forecast for 2026?

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Novo Nordisk A/S is $65.56, with a high forecast of $175.00 and a low forecast of $40.00.

Should I buy or sell Novo Nordisk A/S stock right now?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There is currently 1 sell rating, 18 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.

Does Novo Nordisk A/S's stock price have much upside?

According to analysts, Novo Nordisk A/S's stock has a predicted upside of 46.12% based on their 12-month stock forecasts.

Has Novo Nordisk A/S been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Novo Nordisk A/S's stock had 7 downgrades and 5 upgrades by analysts.

What analysts cover Novo Nordisk A/S?

Novo Nordisk A/S has been rated by research analysts at BMO Capital Markets, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., Kepler Capital Markets, Morgan Stanley, Nordea Equity Research, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Weiss Ratings, Wolfe Research, and Zacks Research in the past 90 days.

Do Wall Street analysts like Novo Nordisk A/S more than its competitors?

Analysts like Novo Nordisk A/S less than other "medical" companies. The consensus rating score for Novo Nordisk A/S is 2.13 while the average consensus rating score for "medical" companies is 2.30. Learn more on how NVO compares to other companies.